Trial 2N-15-7


A Phase 2 Study of TH-4000 in Patients with EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Biological Response Modifier
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Barbara Gitlitz, M.D.
Other Trial Staff:  Lagrimas Ilagan, D.M., Gina Tse, R.N., Eduardo Mejia, D.M., Taison Tran, Coordinator, Laurie De Oliveira, Coordinator, Shandra Edwards, D.M., Kristy Watkins, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.